Last reviewed · How we verify
Eurax (CROTAMITON)
Eurax (Crotamiton) is a small molecule drug originally developed by Ranbaxy and currently owned by Journey. It is used to treat infestation by Sarcoptes scabiei var hominis and itching of the skin. Eurax is an off-patent medication with no active Orange Book patents, making it available as a generic. It has been FDA-approved since 1949. As a crotamiton, Eurax works by reducing itching and killing scabies mites.
At a glance
| Generic name | CROTAMITON |
|---|---|
| Sponsor | Journey |
| Drug class | crotamiton |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
| First approval | 1949 |
Approved indications
- Infestation by Sarcoptes scabiei var hominis
- Itching of skin
Common side effects
- dermititis
- pruritus
- rash
- allergic sensitivity reactions
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Eurax CI brief — competitive landscape report
- Eurax updates RSS · CI watch RSS
- Journey portfolio CI